Travere Therapeutics (TVTX) Competitors $20.04 +0.43 (+2.19%) As of 12:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVTX vs. RGC, RNA, AXSM, ABVX, NUVL, MRUS, CRSP, TGTX, CYTK, and AAPGShould you be buying Travere Therapeutics stock or one of its competitors? The main competitors of Travere Therapeutics include Regencell Bioscience (RGC), Avidity Biosciences (RNA), Axsome Therapeutics (AXSM), Abivax (ABVX), Nuvalent (NUVL), Merus (MRUS), CRISPR Therapeutics (CRSP), TG Therapeutics (TGTX), Cytokinetics (CYTK), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Travere Therapeutics vs. Its Competitors Regencell Bioscience Avidity Biosciences Axsome Therapeutics Abivax Nuvalent Merus CRISPR Therapeutics TG Therapeutics Cytokinetics Ascentage Pharma Group International Travere Therapeutics (NASDAQ:TVTX) and Regencell Bioscience (NASDAQ:RGC) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability. Which has stronger valuation and earnings, TVTX or RGC? Regencell Bioscience has lower revenue, but higher earnings than Travere Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$333.87M5.35-$321.55M-$2.04-9.82Regencell BioscienceN/AN/A-$4.30MN/AN/A Does the media favor TVTX or RGC? In the previous week, Travere Therapeutics had 18 more articles in the media than Regencell Bioscience. MarketBeat recorded 18 mentions for Travere Therapeutics and 0 mentions for Regencell Bioscience. Travere Therapeutics' average media sentiment score of 0.88 beat Regencell Bioscience's score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Travere Therapeutics Positive Regencell Bioscience Neutral Which has more risk and volatility, TVTX or RGC? Travere Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. Comparatively, Regencell Bioscience has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Do analysts recommend TVTX or RGC? Travere Therapeutics presently has a consensus price target of $33.43, indicating a potential upside of 66.81%. Given Travere Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Travere Therapeutics is more favorable than Regencell Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87Regencell Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders have more ownership in TVTX or RGC? 0.1% of Regencell Bioscience shares are held by institutional investors. 4.2% of Travere Therapeutics shares are held by insiders. Comparatively, 2.0% of Regencell Bioscience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is TVTX or RGC more profitable? Regencell Bioscience has a net margin of 0.00% compared to Travere Therapeutics' net margin of -50.64%. Regencell Bioscience's return on equity of 0.00% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-50.64% -717.68% -30.69% Regencell Bioscience N/A N/A N/A SummaryTravere Therapeutics beats Regencell Bioscience on 7 of the 13 factors compared between the two stocks. Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVTX vs. The Competition Export to ExcelMetricTravere TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78B$3.10B$5.76B$9.85BDividend YieldN/A2.28%6.66%4.49%P/E Ratio-9.7920.9382.4826.51Price / Sales5.35367.07500.41161.56Price / CashN/A43.5325.7028.92Price / Book54.168.0510.816.51Net Income-$321.55M-$53.35M$3.28B$266.22M7 Day Performance13.22%-0.93%-0.43%-1.21%1 Month Performance25.56%5.97%6.47%3.32%1 Year Performance99.40%10.33%49.57%23.49% Travere Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVTXTravere Therapeutics2.1612 of 5 stars$20.04+2.2%$33.43+66.8%+104.3%$1.78B$333.87M-9.79460News CoverageAnalyst UpgradeAnalyst RevisionRGCRegencell Bioscience0.0145 of 5 stars$12.28-4.1%N/AN/A$6.33BN/A0.0010Gap DownRNAAvidity Biosciences3.1991 of 5 stars$45.27-2.3%$67.00+48.0%+16.1%$5.96B$10.90M-12.72190Positive NewsAXSMAxsome Therapeutics4.7729 of 5 stars$116.31-1.9%$178.00+53.0%+36.1%$5.91B$385.69M-22.94380News CoveragePositive NewsAnalyst ForecastInsider TradeABVXAbivax3.2547 of 5 stars$77.46+0.2%$92.33+19.2%+574.1%$5.84BN/A0.0061News CoveragePositive NewsShort Interest ↓NUVLNuvalent3.2422 of 5 stars$74.05-2.7%$118.91+60.6%-4.9%$5.49BN/A-15.1140News CoveragePositive NewsAnalyst ForecastMRUSMerus3.0238 of 5 stars$65.74-2.6%$88.64+34.8%+32.0%$5.10B$36.13M-11.9537News CoveragePositive NewsCRSPCRISPR Therapeutics3.5882 of 5 stars$54.13-0.3%$71.60+32.3%+16.4%$4.94B$37.31M-9.97460Analyst RevisionTGTXTG Therapeutics4.3988 of 5 stars$28.53-3.1%$46.25+62.1%+40.2%$4.67B$329M77.11290News CoveragePositive NewsCYTKCytokinetics4.1774 of 5 stars$37.01-3.5%$71.58+93.4%-8.4%$4.59B$85.74M-7.26250Trending NewsAnalyst ForecastInsider TradeOptions VolumeAAPGAscentage Pharma Group InternationalN/A$43.48-9.2%N/AN/A$4.45B$134.35M0.00600Gap DownHigh Trading Volume Related Companies and Tools Related Companies Regencell Bioscience Competitors Avidity Biosciences Competitors Axsome Therapeutics Competitors Abivax Competitors Nuvalent Competitors Merus Competitors CRISPR Therapeutics Competitors TG Therapeutics Competitors Cytokinetics Competitors Ascentage Pharma Group International Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVTX) was last updated on 9/4/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredFree: The Crypto Summit That Could Change Your Life27 industry leaders share urgent market intel (free access)... For a very limited time, you can claim your ...Crypto 101 Media | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TVTX Stock Alerts